MENU
American flag

Resource4DefectiveDrugs.com

CALL FOR A FREE CASE REVIEW 1-800-613-9000

Tap to Call Anytime
Se Habla Español

Absorb GT1 Bioresorbable Vascular Scaffold (BVS) by Abbott Vascular: Letter to Health Care Providers – FDA Investigating Increased Rate of Major Adverse Cardiac Events

Absorb GT1 Bioresorbable Vascular Scaffold (BVS) by Abbott Vascular: Letter to Health Care Providers – FDA Investigating Increased Rate of Major Adverse Cardiac Events

The FDA is informing health care providers treating patients with Absorb GT1 Bioresorbable Vascular Scaffold (BVS) that there is an increased rate of major adverse cardiac events observed in patients receiving the BVS, when compared to patients treated with the approved metallic XIENCE drug-eluting stent.

Full Article: Absorb GT1 Bioresorbable Vascular Scaffold (BVS) by Abbott Vascular: Letter to Health Care Providers – FDA Investigating Increased Rate of Major Adverse Cardiac Events – fda.gov.


Viberzi (eluxadoline): Drug Safety Communication – Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder

Viberzi (eluxadoline): Drug Safety Communication – Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder

FDA is warning that Viberzi (eluxadoline), a medicine used to treat irritable bowel syndrome with diarrhea (IBS-D), should not be used in patients who do not have a gallbladder. An FDA review found these patients have an increased risk of developing serious pancreatitis that could result in hospitalization or death. Pancreatitis may be caused by spasm of a certain digestive system muscle in the small intestine. As a result, FDA is working with the Viberzi manufacturer, Allergan, to address these safety concerns.

Full Article: Viberzi (eluxadoline): Drug Safety Communication – Increased Risk of Serious Pancreatitis In Patients Without A Gallbladder – fda.gov.


Balloon angioplasty devices to treat autonomic dysfunction: FDA Safety Communication – FDA concern over experimental procedures

Balloon angioplasty devices to treat autonomic dysfunction: FDA Safety Communication – FDA concern over experimental procedures

FDA is alerting the public about an experimental procedure called Transvascular Autonomic Modulation (TVAM). This procedure may put patients at risk because is being promoted as treatment for a variety of conditions even though it has not been formally studied in clinical trials. The procedure uses balloon angioplasty devices outside the scope of the FDA-approved indications for use.

Full Article: Balloon angioplasty devices to treat autonomic dysfunction: FDA Safety Communication – FDA concern over experimental procedures – fda.gov.


Comprehensive Reverse Shoulder by Zimmer Biomet: Class I Recall – High Fracture Rate

Comprehensive Reverse Shoulder by Zimmer Biomet: Class I Recall – High Fracture Rate

Zimmer Biomet is recalling the Comprehensive Reverse Shoulder because these devices are fracturing at a higher rate than is stated in the labeling. Fractures may result in revision surgeries which could cause serious adverse health consequences such as permanent loss of shoulder function, infection, or rarely, death.

Full Article: Comprehensive Reverse Shoulder by Zimmer Biomet: Class I Recall – High Fracture Rate – fda.gov.


PNC-27 Products: FDA Warning – Do Not Use For Treatment or Cure for Cancer

PNC-27 Products: FDA Warning – Do Not Use For Treatment or Cure for Cancer

FDA is warning consumers not to purchase or use PNC-27, a product promoted and sold through http://PNC27.com, as a treatment or cure for cancer. An FDA laboratory discovered the bacteria Variovorax paradoxus in a PNC-27 solution sample for inhalation.

Full Article: PNC-27 Products: FDA Warning – Do Not Use For Treatment or Cure for Cancer – fda.gov.